Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DNTH 
Dianthus Therapeutics Inc. (DNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: DNTH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $52.51
1 Year Target Price $52.51
| 10 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 43.87% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 798.59M USD | Price to earnings Ratio - | 1Y Target Price 52.51 |
Price to earnings Ratio - | 1Y Target Price 52.51 | ||
Volume (30-day avg) 12 | Beta - | 52 Weeks Range 13.37 - 32.27 | Updated Date 08/29/2025 |
52 Weeks Range 13.37 - 32.27 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.53 | Actual -0.88 |
Profitability
Profit Margin - | Operating Margin (TTM) -18096.89% |
Management Effectiveness
Return on Assets (TTM) -23.37% | Return on Equity (TTM) -34.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 542533839 | Price to Sales(TTM) 164.52 |
Enterprise Value 542533839 | Price to Sales(TTM) 164.52 | ||
Enterprise Value to Revenue 111.77 | Enterprise Value to EBITDA -7.35 | Shares Outstanding 32188300 | Shares Floating 13459235 |
Shares Outstanding 32188300 | Shares Floating 13459235 | ||
Percent Insiders 7.86 | Percent Institutions 122.93 |
Upturn AI SWOT
Dianthus Therapeutics Inc.
Company Overview
History and Background
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics to treat complement-mediated diseases. Founded in 2019, it is focused on developing best-in-class monoclonal antibodies that selectively inhibit the classical complement pathway. The company went public in 2024.
Core Business Areas
- Drug Development: Discovery and development of monoclonal antibodies to treat complement-mediated diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Innovation: Focusing on innovative research to enhance the existing products or developing new ones.
Leadership and Structure
The leadership team includes experienced executives and scientists in the biotechnology industry. The company has a board of directors overseeing its strategic direction and governance.
Top Products and Market Share
Key Offerings
- DNTH103: DNTH103 is a lead product, a potent and selective inhibitor of the classical complement pathway, potentially treating generalized myasthenia gravis (gMG) and other autoimmune diseases. Market share data and specific revenue figures are not yet publicly available as the product is still in clinical trials. Competitors are companies developing complement inhibitors, such as UCB with Zilucoplan, Alexion Pharmaceuticals (acquired by AstraZeneca) with Soliris and Ultomiris, and argenx with Efgartigimod.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant investment requirements. The market for complement inhibitors is growing due to the increasing prevalence of autoimmune diseases.
Positioning
Dianthus Therapeutics is positioning itself as a leader in the development of selective complement inhibitors, focusing on the classical pathway. Its competitive advantage lies in the potential for improved efficacy and safety compared to existing therapies.
Total Addressable Market (TAM)
The TAM for complement inhibitors in autoimmune diseases is estimated to be in the billions of dollars. Dianthus Therapeutics is focused on capturing a significant portion of this market by developing best-in-class therapies, starting with DNTH103.
Upturn SWOT Analysis
Strengths
- Potent and selective complement inhibitor
- Experienced management team
- Strong intellectual property portfolio
- Promising clinical trial results
Weaknesses
- Dependence on a single lead product (DNTH103)
- High cash burn rate
- Limited commercialization experience
- Reliance on future clinical trial success
Opportunities
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Potential for breakthrough therapy designation
- Increasing market demand for complement inhibitors
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Patent challenges
Competitors and Market Share
Key Competitors
- UCB (UCBJF)
- AstraZeneca (AZN)
- argenx (ARGX)
Competitive Landscape
Dianthus Therapeutics faces competition from established pharmaceutical companies with marketed complement inhibitors and other companies developing novel therapies. Its success will depend on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as Dianthus Therapeutics is a newly public company.
Future Projections: Future growth is dependent on the successful development and commercialization of DNTH103 and other pipeline products. Analyst estimates are not yet available.
Recent Initiatives: Recent initiatives include advancing DNTH103 through clinical trials, exploring new indications for its complement inhibitors, and strengthening its intellectual property portfolio.
Summary
Dianthus Therapeutics is an early-stage biotechnology company focused on complement-mediated diseases, primarily through its DNTH103 product. While promising clinical trial results present strengths, the company faces weaknesses due to its reliance on a single product and limited commercial experience. The company must demonstrate that it can successfully navigate the regulatory and clinical trail environment to ensure its success against the competition. Its future success hinges on advancing its pipeline and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Information is based on publicly available data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dianthus Therapeutics Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2023-09-12 | President, CEO & Director Mr. Marino Garcia M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://dianthustx.com |
Full time employees 78 | Website https://dianthustx.com | ||
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.